Visual and Electrochemical Detection of let-7a: A Tumor Suppressor and Biomarker

Zhen Song1, Qiang-Yan Zhang1, Jia-Jing Li1

  • 1Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, P. R. China.

PubMed

Insights

This study presents a sensitive method for detecting let-7a, a microRNA crucial for cancer suppression. The new technique utilizes hybridization chain reaction coupled with lateral flow assay or electrochemical impedance spectroscopy for accurate cancer biomarker detection.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Background:

  • Let-7a microRNA is a low-expressed biomarker in cancer cells, significant for tumor suppression.
  • Sensitive detection methods for let-7a are vital for cancer diagnosis and therapeutic strategies.
  • Hybridization chain reaction (HCR) offers a promising platform for amplifying microRNA signals.

Purpose of the Study:

  • To develop simple and sensitive detection methods for let-7a.
  • To explore the utility of HCR initiated by let-7a for subsequent detection via Lateral Flow Assay (LFA) and Electrochemical Impedance Spectroscopy (EIS).
  • To establish a quantitative detection range and limit for let-7a.

Main Methods:

  • Initiation of HCR using let-7a and two hairpin primers (H1 and H2).
  • Detection of HCR products using LFA with biotin-modified H1 (bio-H1) and free H2.
  • Electrochemical detection using an H1'-AuNP-modified electrode to measure impedance changes (ΔRct) after HCR.

Main Results:

  • LFA showed a color change on the T line that increased as let-7a concentration decreased.
  • Electrochemical method detected let-7a in the range of 10.0 fM to 1.0 nM.
  • The electrochemical method achieved a detection limit of 4.2 fM for let-7a.

Conclusions:

  • The developed HCR-based methods provide sensitive and simple approaches for let-7a detection.
  • Both LFA and EIS coupled with HCR are effective for quantifying let-7a, with EIS demonstrating a lower detection limit.
  • These methods hold potential for advancing cancer diagnostics and monitoring therapeutic responses.